Skip to main content
OpenTrials
Completed

NCT Number: NCT01338441

Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples

The study main objective is to assess the changes in the ventricular repolarization (measure by the delta QTcf) after drug induced stimulation, compare to placebo, in order to identify subjects with extreme responses and collecting their skin and blood samples.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

BIOTRIAL

Rueil-Malmaison, 92500, France

About this study

An ECG is performed after a dose of sotalol on about 100 healthy subjects in order to identify about 20 extreme responders (10 high responders and 10 non responders) assessed as Delta QTcf compare to baseline. The ECG will be measured and the delta QTcf will be calculated on the 20 selected subjects in a second part of the clinical trial, cross over erythromycin/placebo.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 to 40 years of age
  • Caucasian origin
  • BMI 19 to 29 kg/m²
  • Informed Consent obtained
  • National Health Security Number
  • Eligible for Phase I as mentioned in the national registry of healthy volunteers
  • For woman: use of an effective contraceptive method

Non Inclusion Criteria:

  • Asthma
  • Heart Rate < 50 bpm
  • Hypotension with systolic blood pressure< 100 mm Hg.
  • atrioventricular block (PR interval > 200 ms)
  • Known Chronic illness (hepatic, renal or cardiac impairment, etc..)
  • Raynaud's phenomenon
  • Drug known to prolong QT (http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm) in the last 7 days.
  • All chronic treatments are forbidden exceptive : oral contraceptives, paracetamol, vitamins and comfort treatment that do not prolong the QT
  • Known family or individual past history of QT prolongation or unexplained syncope
  • (QTcF) > 450 ms
  • QRS interval non assessable on ECG at rest or bundle-branch block, QRS > 100 ms
  • Allergy to macrolide type antibiotics
  • Known allergy to sotalol or lidocaine
  • Positive blood pregnancy test (Inclusion visit)
  • Known abnormal haemostasis
  • Kaliemia< 3.5 mmol/L
  • Magnesemia< 0,7 mmol/L
  • Under exclusion period or participating to another clinical trial on a new medicinal product
  • Creatinin clearance < 80 ml/min (Cockroft and Gault formula)
  • AST-ALT >3x upper normal limit

Treatment and study plan

Erythromycin

Drug

4mg/Kg, IV during 20 min once

Placebo

Drug

4mg/Kg, IV during 20 min once

Primary outcomes

  1. Prolongation of cardiac QT due to erythromycin compare to Placebo reported as Delta QTcf

    Time frame: 1hour and 20 minutes

    Delta QTcf is measured at H0, H0+20 minutes, and H0+1h20, on groups' erythromycin and placebo. QTcf may be adjusted based on the pharmacokinetic data to ensure time of the plasmatic pick is used.

Secondary outcomes

  1. Comparison Delta QTcf eryhtromycin-sotalol

    Time frame: over 3 hours

    compare the effect of erythromycin and sotalol on QT prologation

  2. Assess the effect of erythromycin Twave morphologie changes

    Time frame: 1hour and 20 min

    Analysis of Qwave morphologic changes

Sponsors and collaborators

Lead sponsor

Ectycell SASU

Industry

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France
  • Pierre and Marie Curie University

Registry information

Official study title

Selections of Subjects With Dramatic Changes in Their Cardiac Repolarization Parameters After a Pharmacologic Stimulus Aiming to Collect Their Skin Biopsy and Blood Cells

Acronym: iQTEST

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Apr 19, 2011
Registry last updated
Sep 15, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.